8-K: reAlpha Tech Faces Nasdaq Delisting Risk After Board Resignations

reAlpha Tech Corp. reported the resignations of two directors, leading to non-compliance with Nasdaq's audit committee requirements and triggering a cure period.

Summary

• Brian Cole and Monaz Karkaria resigned from reAlpha Tech Corp.'s Board of Directors on February 4, 2026, and February 5, 2026, respectively, effective immediately.
• Mr. Cole's resignation created a vacancy on the Audit Committee, reducing its members to two.
• This reduction resulted in reAlpha Tech Corp. being non-compliant with Nasdaq Listing Rule 5605(c)(2)(A), which requires an Audit Committee of three independent members.
• The Company notified Nasdaq of its non-compliance on February 6, 2026, and intends to rely on the provided cure period.
• reAlpha Tech Corp. plans to appoint a third director to the Audit Committee who meets the required criteria by the earliest of its next annual meeting of stockholders or 180 days after Mr. Cole's resignation.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the board resignations and immediate non-compliance with Nasdaq listing rules. While a cure period exists, the situation introduces governance uncertainty and potential for negative investor sentiment.

Positives

• The Company has a defined cure period from Nasdaq to regain compliance with listing rules.
• Management explicitly stated that the resignations were not due to disagreements with the Company's operations, policies, or practices.

Negatives

• Two directors, Brian Cole and Monaz Karkaria, resigned from the Board of Directors.
• The Company is currently non-compliant with Nasdaq Listing Rule 5605(c)(2)(A) regarding the composition of its Audit Committee.
• The non-compliance creates uncertainty regarding the Company's continued listing on The Nasdaq Stock Market LLC.

Risks

• Risk of delisting from The Nasdaq Stock Market LLC if the Company fails to appoint a qualified third director to the Audit Committee within the cure period.
• Potential for negative investor perception due to board resignations and governance non-compliance.
• Uncertainty regarding the Company's ability to attract and appoint a suitable independent director to the Audit Committee in a timely manner.

Future Outlook

The Company intends to appoint a new director to its Board and the Audit Committee prior to the end of the cure period and is committed to regaining and maintaining compliance with Nasdaq rules.

Management Comments

• The resignations of Brian Cole and Monaz Karkaria were not the result of any disagreements with the Company relating to its operations, policies, or practices.

Industry Context

StockSavvy.ai notes that maintaining compliance with exchange listing standards, particularly regarding independent audit committee composition, is a fundamental aspect of sound corporate governance and investor confidence in the public markets. Non-compliance, even with a cure period, can signal instability and raise questions about oversight, potentially impacting market perception compared to peers with robust governance structures.

Comparison to Industry Standards

• The requirement for a three-member independent audit committee is a standard corporate governance benchmark across major U.S. exchanges, including Nasdaq, designed to ensure financial reporting integrity and investor protection.
• Companies like Apple Inc. and Microsoft Corp. consistently maintain fully compliant and independent audit committees, setting a high bar for governance standards.
• Failure to meet these standards, even temporarily, places reAlpha Tech Corp. below typical industry best practices for publicly traded companies, which prioritize strong independent oversight.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to governance concerns and the risk of delisting from Nasdaq.
• Investors: Increased scrutiny on the Company's corporate governance practices and ability to maintain listing standards.

Next Steps

• Appoint a third director to the Audit Committee who satisfies Nasdaq's independence criteria.
• Regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) within the cure period (earliest of next annual meeting or 180 days after Mr. Cole's resignation).

Key Dates

Recommendation

A seasoned investor would likely place a 'hold' recommendation on reAlpha Tech Corp. following this filing. While the immediate non-compliance with Nasdaq rules and the resignation of two directors are negative governance signals, the Company has a defined cure period and has expressed its intent to regain compliance. This situation introduces significant uncertainty and risk, but the company's proactive notification to Nasdaq and stated plan to appoint a new director suggest a path to resolution. Investors should monitor the Company's progress in appointing a new independent director to the Audit Committee and regaining Nasdaq compliance before making further investment decisions.

Keywords

reAlpha Tech Corp, AIRE, Nasdaq, delisting, board resignation, audit committee, corporate governance, SEC filing, 8-K